Medytox, Korea’s first botulinum toxin developer, has voiced its objections to the United States International Trade Commission’s (USITC) recent decision to acquit Hugel, another Korean medical aesthetics company, of stealing Medytox’s botulinum toxin strains.

Complaining about the commission’s final ruling made on Thursday (local time), Medytox said Friday that it will take all possible measures to protect its intellectual property.

The company is expected to lodge an appeal with a U.S. appellate court or the U.S. president, who has the right to overturn the commission’s decision.

“The full commission made a wrong decision,” a Medytox official said. “We will take all possible measures to reveal the truth in the end.”

The final ruling came four months after the USITC’s initial decision in June, which was also in favor of Hugel.

The administrative law judge for the USITC’s investigation reiterated that “there is no violation of Section 337” based on Medytox’s 토토 allegation of unfair practices concerning the importation of certain botulinum toxin products into the U.S.

“With the USITC’s final determination clearing any uncertainties surrounding Hugel’s business operations in the U.S., we will accelerate our business expansion in the U.S.,” a Hugel official said.

“We will strive to strengthen corporate credibility and shareholder value and will seek continuous growth in global markets,” the Hugel official added.

As a result of the decision, Hugel has been allowed to roll out its Letybo botulinum toxin product in the U.S. market.